Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock
September 04, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
August 20, 2024 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces New Additions and Changes to Its Board of Directors
August 14, 2024 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
July 25, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock
July 22, 2024 16:05 ET
|
Windtree Therapeutics
$12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares The Company...
Windtree Therapeutics Regains Compliance with Nasdaq
May 07, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Announces Reverse Stock Split
April 18, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
April 17, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
April 08, 2024 16:48 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an...
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
February 01, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...